# Clarification of Optimal Anticoagulation Through Genetics

> **NCT00839657** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 1015 (actual)

## Conditions studied

- Stroke
- Venous Thrombosis
- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **BEHAVIORAL:** Genotype-guided dosing algorithm for warfarin
- **BEHAVIORAL:** Clinical-guided dosing algorithm for warfarin

## Key facts

- **NCT ID:** NCT00839657
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-04
- **Final completion:** 2013-11
- **Target enrollment:** 1015 (ACTUAL)
- **Last updated:** 2016-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839657, "Clarification of Optimal Anticoagulation Through Genetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00839657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*